A Study of EXG102-031 in Patients With wAMD (Everest) (NCT05903794) | Clinical Trial Compass
CompletedPhase 1
A Study of EXG102-031 in Patients With wAMD (Everest)
United States12 participantsStarted 2023-07-24
Plain-language summary
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD.
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female, age ≥ 50 years of age;
✓. Diagnosis of nAMD and current active lesion in the study eye at Screening;
✓. An ETDRS BCVA letter scores between 73 and 19 letters in the study eye;
✓. Response to anti-VEGF treatment during Screening;
✓. The study eye must be a pseudophakic lens (post-cataract surgery status); and
✓. Voluntarily agree to participate in the clinical trial, understand the trial procedures, and be capable of signing the informed consent form before screening.
Exclusion criteria
✕. Presence of any ocular disease or history of disease in the study eye other than nAMD that may affect central visual acuity and/or macular detection, including retinal detachment, or in the opinion of the investigator could limit VA improvement in the study eye;
✕. Presence in the study eye of CNV or macular edema due to causes other than AMD;